2. Search Result
Search Result
Results for "

tube formation

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

5

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0765
    Isoliquiritin
    1 Publications Verification

    		 Fungal Infection Neurological Disease Inflammation/Immunology
    Isoliquiritin, isolated from Licorice Root, inhibits angiogenesis and tube formation. Isoliquiritin also exhibits antidepressant-like, anti-oxidative, anti-Inflammatory effects and antifungal activity .
    Isoliquiritin
  • HY-115436
    LYG-202

    		Apoptosis Cancer
    LYG-202, a flavonoid, has potent anti-angiogenic and antitumor activity. LYG-202 inhibits VEGF-stimulated HUVEC migration and tube formation. LYG-202 induces cancer cell apoptosis .
    LYG-202
  • HY-P99768
    Olinvacimab

    TTAC-0001

    		 VEGFR Cancer
    Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
    Olinvacimab
  • HY-119726
    Fosmanogepix

    APX001; E1211

    		 Fungal Infection Inflammation/Immunology
    Fosmanogepix (APX001) is a broad-spectrum agent against invasive fungal infections. Fosmanogepix (APX001) targets the conserved Gwt1 enzyme required for the localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi. This inhibition prevents the appropriate localization of cell wall mannoproteins, which compromises cell wall integrity, biofilm formation, germ tube formation, and fungal growth. Fosmanogepix (APX001) can be used for invasive fungal infections research .
    Fosmanogepix
  • HY-133924
    18-Deoxyherboxidiene

    RQN-18690A

    		 Others Cardiovascular Disease Cancer
    18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research .
    18-Deoxyherboxidiene
  • HY-W440983
    SDPC

    PC(18:0/22:6); DHA-PC; 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine

    		 PPAR Cardiovascular Disease Cancer
    SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research .
    SDPC
  • HY-117595
    PHM16

    		FAK FGFR Apoptosis Cancer
    PHM16 is an ATP competitive inhibitor of FAK and FGFR2 (IC50: 0.4 μM and 0.37 μM, respectively), with direct potent anti-angiogenic activity .
    PHM16
  • HY-151982
    Tubulin polymerization-IN-39

    		Microtubule/Tubulin Cardiovascular Disease Cancer
    Tubulin polymerization-IN-39 is a tubulin polymerization inhibitor (IC50: 4.9 μM). Tubulin polymerization-IN-39 occupies the colchicine-binding site. Tubulin polymerization-IN-39 inhibits cancer cell proliferation .
    Tubulin polymerization-IN-39
  • HY-146778
    Tubulin inhibitor 25

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 25 is a potent tubulin inhibitor with an IC50 value of 0.98 μM. Tubulin inhibitor 25 exhibits remarkable activity against cancer cell line HT29. Tubulin inhibitor 25 displays the potent inhibition on cell migration and tube formation that contributes to the anti-angiogenesis .
    Tubulin inhibitor 25
  • HY-113571
    Tie2 kinase inhibitor 2

    		Tie Cardiovascular Disease
    Tie2 kinase inhibitor 2 (compound 7) is a selective Tie2 kinase inhibitor with an IC50 value of 1 μM. Tie2 kinase inhibitor 2 inhibits endothelial cell tube formation, and can be used for Tie2-mediated angiogenic disorders research .
    Tie2 kinase inhibitor 2
  • HY-119726A
    Fosmanogepix (tautomerism)

    APX001 (tautomerism); E1211 (tautomerism)

    		 Fungal Infection Inflammation/Immunology
    Fosmanogepix tautomerism (APX001 tautomerism) is a broad-spectrum and orally active anti-invasive fungal compound. Fosmanogepix tautomerism targets the conserved Gwt1 enzyme required for the localization of glycosylphosphatidylinositol-anchored mannoproteins in fungi, and inhibition prevents proper localization of cell wall mannoproteins, thereby impairing cell wall integrity, biofilm formation, germ tube formation, and fungal growth. Fosmanogepix tautomerism can be used to study invasive fungal infections .
    Fosmanogepix (tautomerism)
  • HY-145820
    Tubulin inhibitor 14

    		Apoptosis Microtubule/Tubulin Cancer
    Tubulin inhibitor 14 is a potent NQO2 (quinone oxidoreductase 2) inhibitor with an IC50 of 1.0 μM. Tubulin inhibitor 14 also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a microtubule-destabilizing agent with potential tumor-selectivity and antiangiogenic and vascular disrupting features .
    Tubulin inhibitor 14
  • HY-122753
    SLMP53-1

    		MDM-2/p53 Cancer
    SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .
    SLMP53-1
  • HY-B0601
    Tafluprost acid
    1 Publications Verification

    AFP-172

    		 Prostaglandin Receptor Drug Metabolite Cardiovascular Disease Neurological Disease Endocrinology
    Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma .
    Tafluprost acid
  • HY-146505
    Tubulin polymerization-IN-6

    		Microtubule/Tubulin Apoptosis Reactive Oxygen Species Cancer
    Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor, with an IC50 of 1.09 μM. Tubulin polymerization-IN-6 inhibits cell migration and tube formation and contributes to the anti-angiogenesis. Tubulin polymerization-IN-6 can greatly inhibit tumor growth on HT29 xenograft Balb/c nude mice .
    Tubulin polymerization-IN-6
  • HY-119843
    Asterric Acid

    Dimethylosoic acid; RES-1214-1; TAN 1415A

    		 Others Infection
    Asterric acid is an antibiotic fungal metabolite that completely inhibits the binding of the potent vasoconstrictor endothelin (ET)-1 to the ETA receptor in A10 cells at 0.1 μM.1 Asterric acid derivatives have also been shown to inhibit VEGF-induced tube formation of human umbilical vein endothelial cells at 3-10 μM, which suggests its usefulness as an antiangiogenic agent.
    Asterric Acid
  • HY-N2132
    Flavokawain B
    1 Publications Verification

    Flavokavain B

    		 Apoptosis Cancer
    Flavokawain B (Flavokavain B) is a chalcone isolated from the root extracts of kava-kava plant and a potent apoptosis inducer for inhibiting the growth of various cancer cell lines. Flavokawain B (Flavokavain B) shows strong antiangiogenic activity. Flavokawain B (Flavokavain B) inhibits human brain endothelial cell (HUVEC) migration and tube formation with very low and non-toxic concentrations .
    Flavokawain B
  • HY-147949
    SKLB0565

    		Microtubule/Tubulin Apoptosis Cancer
    SKLB0565 is a potent tubulin inhibitor. SKLB0565 shows significant anti-proliferative activity against CRC (colorectal carcinoma) cell lines, with IC50 values ranging from 0.012 μM to 0.081 μM. SKLB0565 causes G2/M phase arrest and mitochondria-mediated intrinsic apoptosis. SKLB0565 inhibits cell migration and disrupted the tube formation of HUVECs .
    SKLB0565
  • HY-162601
    D-01

    		Histone Methyltransferase HIF/HIF Prolyl-Hydroxylase Cancer
    D-01 is a dual-targeting inhibitor of HIF-1α and EZH2 (IC50: 4.86 μM and 0.99 μM respectively). D-01 inhibits the expression of H3K27me3 protein. D-01 inhibits the migration, clone and the invasion of A549 cells, and also inhibits tube formation of HUVECs. D-01 can be used for research of lung cancer .
    D-01
  • HY-N2132R
    Flavokawain B (Standard)

    		Apoptosis Cancer
    Flavokawain B (Standard) is the analytical standard of Flavokawain B. This product is intended for research and analytical applications. Flavokawain B (Flavokavain B) is a chalcone isolated from the root extracts of kava-kava plant and a potent apoptosis inducer for inhibiting the growth of various cancer cell lines. Flavokawain B (Flavokavain B) shows strong antiangiogenic activity. Flavokawain B (Flavokavain B) inhibits human brain endothelial cell (HUVEC) migration and tube formation with very low and non-toxic concentrations .
    Flavokawain B (Standard)
  • HY-120200
    YF-452

    		VEGFR Cardiovascular Disease Cancer
    YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
    YF-452
  • HY-148877
    AT-533

    		HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK Infection Inflammation/Immunology Cancer
    AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .
    AT-533
  • HY-155721
    22-(4′-py)-JA

    22-(4′-Pyridinecarbonyl) jorunnamycin A

    		 Akt mTOR Cancer
    22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .
    22-(4′-py)-JA
  • HY-N6871
    Abietic acid

    		Bacterial IKK Ferroptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .
    Abietic acid
  • HY-W800162
    VEGFR-2-IN-37

    		VEGFR Cancer
    VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .
    VEGFR-2-IN-37
  • HY-117991
    DW10075

    		Others Cancer
    DW10075 is a novel, highly selective VEGFR inhibitor that targets the VEGF/VEGF receptor (VEGFR) pathway, which has been shown to be an effective anti-angiogenic approach for cancer therapy. Studies have found that DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 among 21 kinases, while having no effect on the other 18 kinases, including FGFR and PDGFR. In human umbilical vein endothelial cells (HUVECs), DW10075 significantly prevented VEGF-induced activation of VEGFR and its downstream signaling, thereby inhibiting VEGF-induced HUVEC proliferation. In addition, DW10075 dose-dependently inhibited VEGF-induced HUVEC migration and tube formation, and suppressed angiogenesis in the rat aortic ring model and the chick embryo chorionic membrane model. DW10075 also exhibited antiproliferative activity against 22 different human cancer cell lines, with IC50 values ranging from 2.2 μmol/L (for U87-MG human glioblastoma cells) to 22.2 μmol/L (for A375 melanoma cells). In the nude mouse U87-MG xenograft tumor model, oral administration of DW10075 significantly inhibited tumor growth and reduced the expression of CD31 and Ki67 in tumor tissues. In summary, DW10075 is a potential anti-tumor angiogenesis agent that deserves further development.
    DW10075

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: